Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis

9 Mar 2020

Abstract excerpt

Oncolytic virotherapy is emerging as a promising therapeutic option for solid tumours. Several oncolytic vectors in clinical testing are based on attenuated viruses; thus, efforts are being taken to develop a new repertoire of oncolytic viruses, based on virulent viral genomes. This possibility, however, raises concerns dealing with the safety features of the virulent phenotypes. We generated a double regulated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32152425
DOI: 10.1038/s41598-020-61275-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysisPMID 32152425Read ↗

Designing herpes viruses as oncolyticsSemantic proximity Read ↗

Rethinking herpes simplex virus: the way to oncolytic agentsSemantic proximity Read ↗

Designer Oncolytic Adenovirus: Coming of AgeSemantic proximity Read ↗

Oncolytic adenoviruses – selective retargeting to tumor cellsSemantic proximity Read ↗

Oncolytic viruses: programmable tumour hunters.Semantic proximity Read ↗

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus ImmunotherapySemantic proximity Read ↗

Replicative oncolytic herpes simplex viruses in combination cancer therapies.Semantic proximity Read ↗

Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.Semantic proximity Read ↗

Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm.Semantic proximity Read ↗

Replicative Oncolytic Adenoviruses in Multimodal Cancer RegimensSemantic proximity Read ↗

Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer CellsSemantic proximity Read ↗

Tumor Tropism of DNA Viruses for Oncolytic VirotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.